David S. Knopman

Neurology
5716 Cleveland St Ste 200
Virginia Beach, VA 23462

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 857 publications

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.

Journal: Neurology
Published: August 05, 2026

TDP-43 subtypes shape transcriptomic signatures in Alzheimer's disease.

TDP-43 subtypes shape transcriptomic signatures in Alzheimer's disease.

Journal: bioRxiv : the preprint server for biology
Published: July 03, 2026

Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.

Genetic Risk for Alzheimer Disease, Midlife Hypertension, and Dementia: The ARIC Neurocognitive Study.

Journal: Neurology
Published: July 01, 2026

Not Lost in Translation: Universality of Clinical-Pathobiologic Correlation in Alzheimer Disease.

Not Lost in Translation: Universality of Clinical-Pathobiologic Correlation in Alzheimer Disease.

Journal: Neurology
Published: June 18, 2026

Frailty as a Modifier of the Associations Between Vascular Risk Factors and Incident Dementia.

Frailty as a Modifier of the Associations Between Vascular Risk Factors and Incident Dementia.

Journal: Neurology
Published: June 10, 2026

Alzheimer Plasma Biomarkers in Mild Cognitive Impairment: Each With Distinct Etiologic and Prognostic Roles.

Alzheimer Plasma Biomarkers in Mild Cognitive Impairment: Each With Distinct Etiologic and Prognostic Roles.

Journal: Neurology
Published: May 04, 2026

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.

Journal: The Lancet. Infectious diseases
Published: April 05, 2026

The UNC13A cryptic exon associates with cognitive impairment in Alzheimer's disease.

The UNC13A cryptic exon associates with cognitive impairment in Alzheimer's disease.

Journal: Alzheimer's research & therapy
Published: April 02, 2026

Contingency of Plasma Dementia Biomarkers on Cognitive Profiles for Prognosis of Incident Dementia: The ARIC Study.

Contingency of Plasma Dementia Biomarkers on Cognitive Profiles for Prognosis of Incident Dementia: The ARIC Study.

Journal: Neurology
Published: March 17, 2026

Mild Behavioral Impairment: A Population-Based Study.

Mild Behavioral Impairment: A Population-Based Study.

Journal: The Journal of neuropsychiatry and clinical neurosciences
Published: March 16, 2026

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL.

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL.

Journal: Clinical trials (London, England)
Published: March 06, 2026

Associations Between Cerebral Microbleed Patterns and Incident Dementia: The ARIC-Neurocognitive Study.

Associations Between Cerebral Microbleed Patterns and Incident Dementia: The ARIC-Neurocognitive Study.

Journal: Stroke
Published: February 27, 2026
Showing 1-12 of 857

Last Updated: 09/26/2026